COSCIENS Biopharma Inc.
CSCID evidence brief
What we can confirm
- Market Cap:
- $5.1M
What it means
What to watch
Prepared research question
What matters most for CSCID—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CSCID
COSCIENS Biopharma Inc. is a biopharmaceutical company focused on the extraction, production, and commercialization of active ingredients from natural sources, with a pipeline of patented technologies and therapeutic assets, but faces significant financial and operational risks including insolvency proceedings in its German subsidiaries.
Key risk: German subsidiary insolvency
Market Cap
$5.1M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
COSCIENS Biopharma Inc. is a biopharmaceutical company focused on the extraction, production, and commercialization of active ingredients from natural sources, with a pipeline of patented technologies and therapeutic assets, but faces significant financial and operational risks including insolvency proceedings in its German subsidiaries.
- COSCIENS Biopharma is involved in the extraction, production, and commercialization of active ingredients from natural sources [sec · filed 2026-04-07].
- The company holds patented technologies and value-driving products under development [sec · filed 2026-03-25].
- As of December 31, 2025, the company reported cash & equivalents of $7.3M and shareholders' equity of $3.8M [sec].
- The company faces insolvency proceedings in respect of its German subsidiaries, which could materially affect its financial position [sec · filed 2026-04-07].
- COSCIENS is heavily dependent on sales from its main distributor of active ingredients and its customers [sec · filed 2026-03-25].
What works
- The company has patented technologies and a portfolio of value-driving products under development, which may offer future revenue potential [sec · filed 2026-03-25].
- Management believes existing cash on hand will be sufficient to fund anticipated operating and capital expenditure requirements for the next 12 months [sec · filed 2026-03-25].
What to weigh
- The company is subject to insolvency proceedings in respect of its German subsidiaries, creating legal and accounting uncertainties [sec · filed 2026-04-07].
- COSCIENS is heavily dependent on sales from its main distributor and its customers, concentrating revenue risk [sec · filed 2026-03-25].
- The company has no committed sources of capital and does not expect significant new revenues from operations in the near future, raising financing risk [sec · filed 2026-03-25].
- Imposition of duties, tariffs, and trade barriers could materially adversely affect the company's business, financial condition, and results of operations [sec · filed 2026-03-25].
From the filings
Quoted directly from source documents.
The company faces insolvency proceedings in its German subsidiaries.
“the results of any insolvency proceedings in respect of the Company's German subsidiaries”
SEC filings · April 7, 2026
The company is heavily dependent on a main distributor for sales.
“our now heavy dependence on sales by and revenue from our main distributor of active ingredients and its customers”
SEC filings · March 25, 2026
The company has no committed sources of capital and does not expect significant new revenues soon.
“we currently have no committed sources of capital and do not currently expect to any significant new or additional sources of revenues from operations in the near future”
SEC filings · March 25, 2026
Trade barriers could materially affect the company.
“the imposition of duties and tariffs and other trade barriers and retaliatory countermeasures implemented by the U.S. and other governments could have a material adverse effect on our business, financial condition and results of operations”
SEC filings · March 25, 2026
Risks & what to watch (4)›
Key risks
- German subsidiary insolvency — Insolvency proceedings in German subsidiaries create legal and accounting uncertainties that could materially affect the company [sec · filed 2026-04-07].
- Distributor concentration
- Financing and capital needs — No committed capital sources and no near-term revenue growth expected; may need additional financing to fund operations [sec · filed 2026-03-25].
- Trade and tariff risks — U.S. and other government trade barriers could materially harm business, financial condition, and results [sec · filed 2026-03-25].
What to watch
- Outcome of insolvency proceedings in German subsidiaries and their impact on financial statements [sec · filed 2026-04-07].
- Ability to secure additional financing or partnerships to fund operations and development [sec · filed 2026-03-25].
- Revenue trends from the main distributor and any changes in distributor relationships [sec · filed 2026-03-25].
- Regulatory and trade policy developments that could affect the company's supply chain and market access [sec · filed 2026-03-25].
Sources: SEC filings · Generated September 17, 2026 · How we verify sources →
Run COSCIENS Biopharma Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available COSCIENS Biopharma Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Short Interest
as of May 20, 2026- % of float
- 0.3%
- Days to cover
- 0.6
- Shares short
- 8,244
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CSCID short interestFrequently asked questions
What is the AI investment thesis for COSCIENS Biopharma Inc.?
COSCIENS Biopharma Inc. is a biopharmaceutical company focused on the extraction, production, and commercialization of active ingredients from natural sources, with a pipeline of patented technologies and therapeutic assets, but faces significant financial and operational risks including insolvency proceedings in its German subsidiaries.
Who is the CEO of COSCIENS Biopharma Inc.?
Mr. Peter Harry Puccetti CFA is the chief executive officer of COSCIENS Biopharma Inc. (CSCID).
Where is COSCIENS Biopharma Inc. headquartered?
COSCIENS Biopharma Inc. (CSCID) is headquartered in Toronto, ON, Canada.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.